 |
 |
Date Announced: 09 Oct 2013
Light scatter will help ophthalmologists determine whether laser or lens replacement surgery is preferable for patients.
NEWPORT BEACH, Calif., Oct. 9, 2013 /PRNewswire/ -- ALPHAEON Corporation, a leader in lifestyle healthcare and wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired an exclusive U.S. license from Visiometrics, S.L. to market the HD Analyzer™ for an undisclosed amount. The HD Analyzer is the first device that provides ophthalmologists with an assessment of light scatter inside the eye, which is essential for early detection of the existence of a cataract, commonly referred to as Dysfunctional Lens Syndrome.
"This agreement embodies ALPHAEON's commitment to provide specialty physicians with technologies that optimize patient outcomes and experiences," said ALPHAEON Chief Executive Officer Robert E. Grant. "Light scatter is an early detector of Dysfunctional Lens Syndrome, making the HD Analyzer critical to patients' understanding of which self-pay vision correction procedure will lead to the best outcomes."
ALPHAEON Chief Physician Officer Dan Durrie, M.D., said, "This is a major breakthrough in our ability to evaluate patients. As a practicing refractive surgeon, the HD Analyzer has become my standard diagnostic procedure when examining a 40 to 60 year-old patient to determine whether I recommend a lens replacement or LASIK."
Visiometrics CEO Jan Bonel said, "After many years and much effort to bring an objective measurement technology to the U.S. market, I am very pleased to form this partnership with ALPHAEON to offer an important early detection device to physicians and patients."
The HD Analyzer is being used by several hundred ophthalmic centers internationally, and clinical validation has been established in more than 20 peer-reviewed publications worldwide. The HD Analyzer's Optical Scatter Index (OSI) assists in the tracking of cataract progression and is an objective measurement of what a patient actually sees.
The patented technology will help ophthalmologists more precisely determine if a 40 to 60 year old patient is better suited for laser vision correction or lens replacement surgery. The device, a Class I product registered with the FDA, is currently manufactured in Irvine, California and will be commercialized by ALPHAEON beginning in January 2014.
With the addition of the HD Analyzer, ALPHAEON continues to rapidly build a broad and diverse portfolio of unique products and services for the lifestyle healthcare, self-pay market. Recent transactions include the U.S. licensing of an advanced botulinum toxin type A neurotoxin under the brand name EVOSYAL™ and TEOXANE Laboratories' full portfolio of next-generation Hyaluronic Acid (HA)-based dermal fillers and cosmeceutical products currently marketed internationally as TEOSYAL®.
Source: Alphaeon
E-mail: via web site
Web Site: www.alphaeon.com
| © 2024 SPIE Europe |
|
